ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

ANIK: Anika Therapeutics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ANIKA THERAPEUTICS INC (NASD)
ANIK	8.03	-0.09	(-1.11%)	Vol. 19,868	15:55 ET

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid, a naturally-occurring, biocompatible polymer found in the body. Due to its unique properties, hyaluronic acid plays an important role in numerous physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues and the transport of molecules to and within cells.

General Information

ANIKA THERAPEUT

32 Wiggins Avenue Bedford, MA 01730 Phone: 781 932-6616 Fax: 781-935-7803 Web: www.anikatherapeutics.com Email: contact@anikatherapeutics.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/04/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	8.12
52 Week High	8.80
52 Week Low	2.96
Beta	1.11
20 Day Moving Average	71,903.50
Target Price Consensus	N/A

% Price Change
4 Week	28.68
12 Week	35.43
YTD	167.10

% Price Change Relative to S&P 500
4 Week	23.77
12 Week	22.25
YTD	118.61

Share Information
Shares Outstanding (millions)	11.44
Market Capitalization (millions)	92.88
Short Ratio	1.81
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/04/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	N/A
30 Days Ago	N/A
60 Days Ago	N/A
90 Days Ago	N/A

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	22.56
PEG Ratio	-

EPS Growth
vs. Previous Year	30.00%
vs. Previous Quarter	62.50%

Sales Growth
vs. Previous Year	17.25%
vs. Previous Quarter:	13.32%

Price Ratios
Price/Book	1.44
Price/Cash Flow	18.27
Price / Sales	2.41

ROE
09/30/09	6.57
06/30/09	6.03
03/31/09	5.91

ROA
09/30/09	4.26
06/30/09	3.92
03/31/09	3.84

Current Ratio
09/30/09	5.97
06/30/09	5.81
03/31/09	6.09

Quick Ratio
09/30/09	5.22
06/30/09	5.04
03/31/09	5.43

Operating Margin
09/30/09	10.62
06/30/09	9.97
03/31/09	9.70

Net Margin
09/30/09	13.54
06/30/09	12.74
03/31/09	12.46

Pre-Tax Margin
09/30/09	13.54
06/30/09	12.74
03/31/09	12.46

Book Value
09/30/09	5.62
06/30/09	5.47
03/31/09	5.39

Inventory Turnover
09/30/09	2.01
06/30/09	2.16
03/31/09	2.48

Debt-to-Equity
09/30/09	0.21
06/30/09	0.22
03/31/09	0.23

Debt to Capital
09/30/09	17.03
06/30/09	17.86
03/31/09	18.59


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research